Skip to main content

Taysha Expands Age Eligibility for Canadian Clinical Trial

November 29, 2023
Taysha Gene Therapies reports on safety and efficacy results for the first patient to receive gene therapy for Rett Syndrome

On November 29, 2023 Taysha Gene Therapies announced that Health Canada has authorized a protocol amendment to the ongoing REVEAL Phase 1/2 adult trial evaluating TSHA-102 that expands eligibility to include patients aged 12 and older with Rett syndrome.

$40M